Oculis Holding AG

OCS chart

Oculis Holding AG news

• Oculis Reports New Phase 2 ACUITY Biomarker Data  Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

  Yahoo Finance · Oct 22, 2:00 AM EDT

• Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

  Yahoo Finance · Oct 20, 2:00 AM EDT

• Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

  Yahoo Finance · Oct 19, 2:00 AM EDT

• Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

  Yahoo Finance · Oct 19, 2:00 AM EDT

• Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

  Yahoo Finance · Oct 7, 2:00 AM EDT

• Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

  Yahoo Finance · Oct 1, 2:00 AM EDT

• Oculis Announces Resignation of Lionel Carnot from Board of Directors

  Yahoo Finance · Sep 30, 4:46 PM EDT

• After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)

  Yahoo Finance · Sep 28, 8:35 AM EDT

• Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

  Yahoo Finance · Sep 23, 5:30 AM EDT

• Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade

  Yahoo Finance · Aug 31, 9:55 AM EDT

• First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

  Yahoo Finance · Aug 24, 4:00 AM EDT

• Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

  Yahoo Finance · Aug 14, 4:05 PM EDT

Oculis Holding AG key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-K6-K2026-09-30
• 6-K6-K2026-08-10
• 6-K6-K2026-08-06
• 6-K6-K2026-06-25
• 6-K6-K2026-06-01
• 6-K6-K2026-05-14
• 6-K6-K2026-05-11
• 6-K6-K2026-04-21
• 6-K6-K2026-03-04
• 20-F20-F2026-03-04
• 6-K6-K2026-03-03
• 6-K6-K2025-11-10

About Oculis Holding AG

Ticker

OCS (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Zug, Switzerland

Incorporated in

Switzerland

Fiscal year end

December 31

SEC CIK

1953530

Frequently asked questions